16.03.2010 • News • Merck & Co.

GTx and U.S. Merck End Collaboration Agreement

GTx and Merck & Co. have agreed to terminate an exclusive license and collaboration agreement effective immediately, GTx said in a regulatory filing. GTx will now not receive any of the future milestone payments or royalties of up to $422 million that it was eligible to receive under the deal, the company said in a filing with the U.S. Securities and Exchange Commission.

The collaboration agreement, dated Nov. 5, 2007, was related to the development and commercialization of selective androgen receptor modulators (SARM) compounds, GTx said.

Merck & Co.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.